Monitor the Chemomab Israel shareholder vote and the closing of the PIPE investment, as these are critical conditions for the merger. The combined company's ability to execute on its precision medicine strategy for nebokitug in RA will be a key driver of long-term value.
Price Chart
Executive Summary
This S-4/A filing by Snowdrift Parent Corp (SCIP) details a proposed reverse merger with Scipher Medicine Corp, a privately-held precision immunology company. Under the terms, Chemomab Israel will domesticate to Delaware and merge into a subsidiary, with Scipher securityholders receiving ~68% ownership of the combined company. The merger is contingent on a $30M-$50M PIPE investment and Nasdaq listing approval, with the combined entity to trade under the ticker SCIP.
Key Facts
- Chemomab Israel shareholders will own ~32% of the combined company pre-PIPE, while Scipher securityholders will own ~68%.
- A concurrent PIPE investment of at least $30M and up to $50M is required to close the merger.
- The combined company will be renamed Scipher Medicine Corp and trade on Nasdaq under the ticker SCIP.
- Chemomab Israel had $6.7M in cash as of June 30, 2026, and an accumulated deficit of $115.6M.
- Scipher had $2.3M in cash as of June 30, 2026, and an accumulated deficit of $328.4M.
- The merger is expected to close in Q4 2026, subject to shareholder and regulatory approvals.
- Holders of Chemomab Israel ADSs will receive contingent value rights (CVRs) tied to nebokitug milestones, with potential payouts of up to $50M.
- The transaction is expected to be accounted for as a reverse asset acquisition with Scipher as the accounting acquirer.
Financial Impact
The merger will result in significant dilution for current Chemomab Israel shareholders, who will own ~26.7% of the combined company post-PIPE (assuming $30M raise). The combined company will have pro forma cash of ~$25.9M as of June 30, 2026.
Risk Factors
- The merger may not close if shareholder approval, PIPE financing, or Nasdaq listing conditions are not met.
- Significant dilution for current Chemomab Israel shareholders.
- The combined company has a history of losses and may require additional capital.
- Nebokitug has not been tested in RA patients, and the precision medicine strategy may fail.
- The CVRs may never pay out if milestones are not achieved.
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001493152-26-047625 |
| Exhibit: ex10-24.htm | 0001493152-26-047625 |
| Exhibit: ex99-3.htm | 0001493152-26-047625 |
| Exhibit: ex99-6.htm | 0001493152-26-047625 |
| Exhibit: ex99-5.htm | 0001493152-26-047625 |
| Exhibit: ex99-4.htm | 0001493152-26-047625 |
| Exhibit: ex99-2.htm | 0001493152-26-047625 |
| Exhibit: ex23-2.htm | 0001493152-26-047625 |
| Exhibit: ex23-1.htm | 0001493152-26-047625 |
| Document: 0001493152-26-047625-index-headers.html | 0001493152-26-047625 |
| Document: 0001493152-26-047625-index.html | 0001493152-26-047625 |
| Document: 0001493152-26-047625.txt | 0001493152-26-047625 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers